Skip to main content
. 2021 Aug 6;80(10):1286–1298. doi: 10.1136/annrheumdis-2021-220884

Figure 1.

Figure 1

A summary of assessments and end-points which should be collected in clinical trials and observational studies of individuals at risk of RA, according to the at-risk population. MSK, musculoskeletal; RA, rheumatoid arthritis.